Zydus Wellness Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Zydus Wellness (NSE: ZYDWEL) is preparing to announce its Q4 FY26 (January–March 2026) financial results for the period ended March 31, 2026. With the stock trading at Rs 1,620 — against a 52-week high of Rs 2,200 and a 1-year return of -14% — the Q4 FY26 results will be a pivotal event for investors monitoring the Consumer Health / Complan / Glucon-D / Everyuth sector.

Analyst consensus estimates for Q4 FY26 stand at Rs 620–680 Cr in revenue and Rs 68–85 Cr in profit after tax, with margin expectations of EBITDA 16–18%. The key growth metric of Revenue +8–10% YoY will be watched alongside FY27 management guidance — which analysts consider the most important output from the Q4 FY26 announcement.

Get free investment predictions and live Q4 result alerts on Univest.

Zydus Wellness Q4 Results 2026 Date

The Zydus Wellness Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to approve the audited consolidated and standalone financial results for the quarter and full year ended March 31, 2026 and consider a final dividend recommendation.

Here is the broader Q4 FY26 earnings calendar for major Indian companies:

For the complete Q4 FY26 results calendar and real-time announcements, visit Univest Blogs.

Why This Quarter Matters

Q4 FY26 is the final quarter of the financial year — it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Zydus Wellness, with a stock return of -14% over the past year, this quarter’s results and FY27 guidance are critical for determining whether the stock can recover or faces continued pressure.

Beyond the headline revenue of Rs 620–680 Cr and PAT of Rs 68–85 Cr, investors will focus on three areas: (1) whether FY27 guidance meets consensus expectations for Revenue +8–10% YoY, (2) whether the EBITDA 16–18% margin is sustainable or under pressure, and (3) the dividend or buyback announcement of Rs 10 per share. A positive surprise on any two of these parameters could drive a meaningful post-results re-rating.

Zydus Wellness Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Brokerages including MOFSL, YES Securities, and JM Financial project Rs 620–680 Cr in revenue (Q3 actual: Rs 578 Cr) and PAT of Rs 68–85 Cr (Q3 actual: Rs 62 Cr). A beat on revenue combined with margin expansion or positive FY27 guidance would be the most positive scenario for the stock.

Screen Zydus Wellness live fundamentals, FII/DII activity, and analyst upgrades on the Univest Screener.

5 Key Factors That Will Drive Zydus Wellness Q4 FY26 Performance

1. Consumer Health / Complan / Glucon-D / Everyuth Sector Demand Momentum

Zydus Wellness operates in the Consumer Health / Complan / Glucon-D / Everyuth sector — one of India’s structurally growing spaces with Q4 FY26 seasonal demand tailwinds. Q4 is typically the strongest quarter for most sectors due to year-end government capex acceleration, housing completions, and consumer spending peaks. Analyst consensus projects Rs 620–680 Cr for Q4 FY26 — versus Rs 578 Cr in Q3 — implying strong execution execution is required. Track live fundamentals on  Univest Screener.

2. Revenue Growth of Revenue +8–10% YoY

The key volume or rate metric of Revenue +8–10% YoY is the single most important operating variable analysts are tracking for Zydus Wellness’s Q4 FY26. A strong performance on this metric validates the structural investment thesis and is expected to drive positive stock price movement on results day. A miss versus consensus would likely trigger downward FY27 estimate revisions.

3. Margin Delivery at EBITDA 16–18%

Q4 FY26 margin expectations of EBITDA 16–18% (versus Q3 actual of EBITDA 16.5%) reflect the interplay of pricing power, input cost management, and operating leverage. If Zydus Wellness can sustain or expand margins while delivering estimated revenue, it would mark a continuation of the profitability improvement story and be positively received by institutional investors.

4. FY27 Guidance — The Single Most Critical Catalyst

The single most consequential output from the Q4 FY26 board meeting will be management’s FY27 guidance — revenue growth bands, margin targets, capex plans, and macro risk commentary. In the current global environment — shaped by US-India tariff negotiations and FII outflows — credible and specific FY27 guidance from Zydus Wellness will be valued more than the reported Q4 number. Monitor guidance announcements in real time on Univest.

5. Dividend or Capital Allocation Signal

Zydus Wellness is expected to consider Rs 10 per share at the Q4 FY26 board meeting. The dividend quantum signals management’s confidence in free cash flow generation. For investors, dividend per share relative to the current market price of Rs 1,620 determines yield proposition and is a factor in institutional portfolio sizing decisions.

5 Risks to Watch in Zydus Wellness Q4 FY26

1. US Tariff Macro Headwinds

The 26% US reciprocal tariff on Indian goods — announced April 2, 2026 — has created FII outflow pressure across Indian equities. For Zydus Wellness, indirect impacts include compresed earnings multiples and institutional de-allocation, even if the company’s own supply chain is not directly affected by the tariff.

2. Results Miss Versus Estimates

If Zydus Wellness’s Q4 FY26 results miss analyst estimates of Rs 620–680 Cr in revenue and Rs 68–85 Cr in PAT, the stock could correct sharply. The percentage correction is typically larger than the percentage miss — particularly for stocks that have underperformed in the prior 12 months.

3. FY27 Guidance Disappointment

If management’s FY27 guidance falls below Street expectations — even with an in-line Q4 print — the stock may decline on forward estimate cuts. Management credibility is a function of historical guidance delivery; any slippage from prior guidance creates a double discount on new projections.

4. Competitive Pressure in Consumer Health / Complan / Glucon-D / Everyuth

The Consumer Health / Complan / Glucon-D / Everyuth sector faces intensifying competition from domestic capacity additions and international entrants. Zydus Wellness’s ability to maintain pricing power, market share, and customer relationships in this environment is a structural risk factor for FY27 estimates.

5. FII Selling and Liquidity Risk

Global risk-off events can trigger concentrated institutional selling that disconnects stock price from underlying fundamentals. Mid- and small-cap stocks like Zydus Wellness are particularly vulnerable to liquidity-driven corrections on results day independent of the reported numbers.

Zydus Wellness Share Price and Analyst Ratings

Zydus Wellness is trading at Rs 1,620 as of April 2026, against a 52-week high of Rs 2,200 and a 52-week low of Rs 1,380. The 1-year return of -14% reflects the macro headwinds of FY26. Analyst 12-month targets range from Rs 2,100 to Rs 2,000, implying potential recovery from current levels contingent on Q4 execution and FY27 guidance delivery.

Download the Univest iOS App or Univest Android App to track Zydus Wellness live price, charts, and receive real-time Q4 result alerts from SEBI-registered analysts.

Conclusion

Zydus Wellness Q4 FY26 results on May 2026 (Expected) will be a key earnings event for investors monitoring the Consumer Health / Complan / Glucon-D / Everyuth sector. With analyst consensus projecting revenue of Rs 620–680 Cr and PAT of Rs 68–85 Cr, the stock at Rs 1,620 offers a risk-reward profile that depends on execution and FY27 guidance credibility. For more Q4 FY26 previews across sectors, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions. For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: What is the Zydus Wellness Q4 results 2026 date?

The Zydus Wellness Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to approve audited Q4 FY26 financial results and consider a final dividend recommendation.

Q: What is the Zydus Wellness Q4 FY26 PAT estimate?

Analysts estimate Zydus Wellness Q4 FY26 PAT in the range of Rs 68–85 Cr, based on revenue of Rs 620–680 Cr and margin of EBITDA 16–18%. Q3 FY26 actual PAT was Rs 62 Cr.

Q: What is Zydus Wellness’s share price ahead of Q4 results?

Zydus Wellness is trading at Rs 1,620 as of April 2026. The 52-week high is Rs 2,200 and the 52-week low is Rs 1,380. The 1-year return is -14% and market capitalisation is Rs 9,200 Cr.

Q: Will Zydus Wellness declare a dividend in Q4 FY26?

Zydus Wellness is expected to consider Rs 10 per share at the Q4 FY26 board meeting. The quantum will be confirmed on the results announcement date.

Q: Which analysts have a Buy rating on Zydus Wellness?

MOFSL (target Rs 2,000), YES Securities (target Rs 2,100) hold Buy ratings. Consult a SEBI-registered financial advisor before investing.

Q: What were Zydus Wellness Q3 FY26 results?

Zydus Wellness reported Q3 FY26 (October–December 2025) revenue of Rs 578 Cr and PAT of Rs 62 Cr, with margin at EBITDA 16.5%. Q3 actuals form the sequential base against which Q4 FY26 estimates are benchmarked.

Q: When do Infosys and TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026 — PAT Rs 13,718 crore and revenue Rs 70,698 crore, with a Rs 31/share final dividend. Full preview at https://univest.in/blogs/tcs-q4-results-2026-date-preview. Infosys Q4 FY26 results are scheduled for April 23, 2026 — FY27 CC revenue guidance is the critical watch. Full preview at https://univest.in/blogs/infosys-q4-results-2026-date-preview.

Q: Is Zydus Wellness a good investment ahead of Q4 results?

This depends on your risk appetite, investment horizon, and portfolio context. Zydus Wellness has compelling factors — Complan+Glucon-D; rural distribution — alongside genuine near-term risks including US tariff macro headwinds and FY27 guidance uncertainty. Analyst consensus targets range from Rs 2,100 to Rs 2,000. Consult a SEBI-registered financial advisor before investing.

Recent Article

Zuari Agro Chemicals Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Zota Health Care Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Zodiac Energy Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Zodiac Clothing Company Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Zim Laboratories Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook